4.7 Article

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 21, Pages 2397-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.20.03643

Keywords

-

Categories

Funding

  1. charity Anthony Nolan
  2. National Cancer Institute (NCI) [U24CA076518]
  3. National Heart, Lung and Blood Institute (NHLBI)
  4. National Institute of Allergy and Infectious Diseases (NIAID)
  5. NHLBI [U24HL138660, U01HL128568]
  6. NCI
  7. Health Resources and Services Administration (HRSA) [HHSH250201700006C, HHSH250201700007C]
  8. Office of Naval Research [N00014-20-1-2705, N00014-20-12832]
  9. BARDA
  10. Match Foundation
  11. Boston Children's Hospital
  12. Dana Farber
  13. St Baldrick's Foundation
  14. Stanford University
  15. Medical College of Wisconsin the National Marrow Donor Program
  16. Actinium Pharmaceuticals Inc.
  17. Adienne SA
  18. Allovir Inc.
  19. Amgen Inc.
  20. Angiocrine Bioscience
  21. Astellas Pharma US
  22. bluebird bio Inc.
  23. Bristol Myers Squibb Co
  24. Celgene Corp
  25. CSL Behring
  26. CytoSen Therapeutics Inc.
  27. Daiichi Sankyo Co, Ltd.
  28. ExcellThera
  29. Fate Therapeutics
  30. Gamida-Cell, Ltd.
  31. Genentech Inc.
  32. Incyte Corporation
  33. Janssen/Johnson Johnson
  34. Jazz Pharmaceuticals Inc.
  35. Kiadis Pharma
  36. Kite, a Gilead Company
  37. Kyowa Kirin
  38. Legend Biotech
  39. Magenta Therapeutics
  40. Merck Sharp Dohme Corp
  41. Millennium, the Takeda Oncology Co
  42. Miltenyi Biotec Inc.
  43. Novartis Pharmaceuticals Corporation
  44. Omeros Corporation
  45. Oncoimmune Inc.
  46. Orca Biosystems Inc.
  47. Pfizer Inc.
  48. Pharmacyclics, LLC
  49. Sanofi Genzyme
  50. Takeda Pharma
  51. Vor Biopharma
  52. Xenikos BV
  53. Stemcyte
  54. [P01CA111412]
  55. [R01CA152108]
  56. [R01CA215134]
  57. [R01CA218285]
  58. [R01CA231141]
  59. [R01AI128775]
  60. [R01HL126589]
  61. [R01HL129472]
  62. [R01HL130388]
  63. [R01HL131731]
  64. [U01AI069197]
  65. [U01AI126612]
  66. [UG1HL06924]

Ask authors/readers for more resources

This study found that UHR HLA matching may not increase overall survival probability, but it does reduce the risk of aGVHD and in certain subsets, transplant-related mortality. Matching at the UHR level warrants consideration when choosing between multiple 10 out of 10 HLA-matched donors.
PURPOSE Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes following unrelated donor hematopoietic cell transplantation, improving survival and reducing post-transplant complications. However, most studies included relatively small numbers of patients. Here we report the findings from a large, multicenter validation study. METHODS UHR HLA typing was available on 5,140 conventionally 10 out of 10 HLA-matched patients with malignant disease transplanted between 2008 and 2017. RESULTS After UHR HLA typing, 82% of pairs remained 10 out of 10 UHR-matched; 12.3% of patients were 12 out of 12 UHR HLA-matched. Compared with 12 out of 12 UHR-matched patients, probabilities of grade 2-4 acute graft-versus-host disease (aGVHD) were significantly increased with UHR mismatches (overall P = .0019) and in those patients who were HLA-DPB1 T-cell epitope permissively mismatched or nonpermissively mismatched (overall P = .0011). In the T-cell-depleted subset, the degree of UHR HLA mismatch was only associated with increased transplant-related mortality (TRM) (overall P = .0068). In the T-cell-replete subset, UHR HLA matching was associated with a lower probability of aGVHD (overall P = .0020); 12 out of 12 UHR matching was associated with reduced TRM risk when compared with HLA-DPB1 T-cell epitope permissively mismatched patients, whereas nonpermissive mismatching resulted in a greater risk (overall P = .0003). CONCLUSION This study did not confirm that UHR 12 out of 12 HLA matching increases the probability of overall survival but does demonstrate that aGVHD risk, and in certain settings TRM, is lowest in UHR HLA-matched pairs and thus warrants consideration when multiple 10 out of 10 HLA-matched donors of equivalent age are available.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available